

Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market in China 2023

<https://marketpublishers.com/r/A918178CF468EN.html>

Date: May 2023

Pages: 37

Price: US\$ 675.00 (Single User License)

ID: A918178CF468EN

Abstracts

Antibiotics for multidrug-resistant Gram-positive bacteria are a critical area of research and development as these types of bacteria have developed resistance to multiple types of antibiotics, making them difficult to treat. Some antibiotics that have been effective in treating certain types of multidrug-resistant Gram-positive bacteria include daptomycin, linezolid, teicoplanin, and tigecycline. The antibiotics for multidrug-resistant gram-positive bacteria market in China is anticipated to increase by USD 3.0 billion till 2029 at an average annual growth of 8.58 percent as per the latest market estimates.

This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and route of administration. The China market data on antibiotics for multidrug-resistant gram-positive bacteria can be segmented by type: daptomycin, linezolid, teicoplanin, tigecycline. Antibiotics for multidrug-resistant gram-positive bacteria market is further segmented by route of administration: injectable, oral.

The competitive landscape of the industry has also been examined along with the profiles of the key players Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?

Get a detailed picture of the China Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market

Identify segments/areas to invest in over the forecast period in the China
Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market
Understand the competitive environment, the market's leading players
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

Part 1. Summary

Part 2. Introduction

Study period

Geographical scope

Market segmentation

Part 3. Antibiotics for multidrug-resistant gram-positive bacteria market overview

Part 4. Market breakdown by type

Daptomycin

Linezolid

Teicoplanin

Tigecycline

Part 5. Market breakdown by route of administration

Injectable

Oral

Part 6. Key companies

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

North China Pharmaceutical Company Ltd.

Pfizer, Inc.

Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhejiang Medicine Co., Ltd.

Part 7. Methodology

I would like to order

Product name: Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market in China 2023

Product link: <https://marketpublishers.com/r/A918178CF468EN.html>

Price: US\$ 675.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A918178CF468EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970